Dimethyl Fumarate (DMF) Observational Study

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Patients.

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD

A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer

KPL-301 for Subjects With Giant Cell Arteritis

Phase 1/2A Dose Escalation Study in CLL, SLL or NHL

Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias

A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)